EYPT - EyePoint Pharmaceuticals GAAP EPS of -$0.55 misses by $0.17 revenue of $11.68M beats by $2.54M
2024-05-08 11:16:37 ET
More on EyePoint Pharmaceuticals
- EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program
- EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
- EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript
- EyePoint tumbles 30% premarket on failed Phase 2 study
- EyePoint Pharmaceuticals GAAP EPS of -$0.33 beats by $0.16, revenue of $14M beats by $5.3M